The most expensive number in pharmaceutical finance is the one nobody on the executive team wants to commit to: how […]

Every time a pharmaceutical company changes something about an approved drug, it opens two doors simultaneously. The first leads to

The pharmaceutical industry has a math problem. A blockbuster drug throws off cash at a rate that makes any other

A composition of matter patent is the only piece of pharmaceutical intellectual property that a generic or biosimilar manufacturer cannot

The composition-of-matter patent is the loudest piece of intellectual property a pharmaceutical company owns. It is also, increasingly, the least

The Biologics Price Competition and Innovation Act turned fifteen years old in March, and the procedural ritual it created keeps

The pharmaceutical industry has always run on information asymmetry. The company that knows, six months before its competitors, that a

A practitioner’s guide for IP teams, generic manufacturers, and pharmaceutical investors who need to decode what a competitor’s formulation patent

There is a moment, familiar to every generic drug executive, when a promising target drug goes from ‘opportunity’ to ‘nightmare.’